This analysis delves into the latest insights on Gilead Sciences. The consensus rating ... with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

Gilead Sciences, Inc. (NASDAQ:GILD ... We look forward to sharing information on our plans for lenacapavir and the rest of our leading HIV portfolio at our HIV Analyst Event on December 10th. We are ...

Gilead Sciences, Inc. (GILD) is currently at $97.23, up $5.54 or 6.04% --Would be highest close since April 27, 2016, when it closed at $100.72 --On pace for largest percent increase since June 20, ...

Operator Good afternoon, everyone, and welcome to Gilead's third quarter 2024 earnings conference call. My name is Rebecca, and I'll be your host for today. In a moment, we'll begin with our prepared ...

Foster City, Calif.-based Gilead (GILD) had net income of $1.25 billion, or $1.00 a share, for the quarter, down from $2.18 billion, or $1.73 a share, in the year-earlier period. Adjusted for one-time ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

There are a whole host of reasons why Ireland has historically succeeded in attracting more than 90 biopharma companies to ...

Creative Media & Community Trust ("CMCT") announced today that it will report its third quarter 2024 earnings results on Friday, November 8, 2024 before the opening of the stock market. A conference ...